Survival in Myelofibrosis Patients After Allogeneic Hematopoietic Stem Cell Transplantation in Five Centers in France

The investigators would like to conduct a retrospective study in five centers in France in the goal to evaluate the survival of patients receiving allogeneic hematopoietic stem cell transplantation for myelofibrosis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Myelofibrosis Bone Marrow Diseases Graft vs Host Disease Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Myeloproliferative Disorders Primary Myelofibrosis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

The allogeneic stem cell transplantation is the only curative treatment for myelofibrosis. However, because of complications such as infection, graft-versus-host disease and conditioning toxicity, this procedure is associated with a high morbidity-mortality rate. The discovery of molecular and genetic markers permitted to improve therapeutic strategy and survival of patient in the last few years. In this study, the investigators want to make an overview of survival, incidence of relapse and incidence of acute and chronic graft versus host disease in allogeneic stem cell transplantation for myelofibrosis, in five centers in France, between 2007 and 2017.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

adult patients receiving allogeneic hematopoietic stem cell transplantation for myelofibrosis in five centers in France (Nancy, Besancon, Strasbourg, Pitie Salpetriere and Lyon) between 2007 and 2017

Exclusion criteria

age < 18 years old

Treatment and study plan

Primary outcomes

survival

Time frame: at 1 year

incidence of survival in the cohort

Secondary outcomes

incidence of relapse

Time frame: at 1 year

incidence of relapse in the cohort
incidence of acute graft versus host disease

Time frame: at 3 months

incidence of acute graft versus host disease in the cohort
incidence of chronic graft versus host disease

Time frame: at 1 year

incidence of chronic graft versus host disease in the cohort

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Registry information

Official study title

Survival in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis in Five French Centers

Acronym: SYMFASCT

Important dates

Study start: 2007
Primary completion: 2017
Study completion: 2020
First posted: Feb 24, 2020
Registry last updated: Mar 12, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed